AIDSWEEKLY Plus; Monday, July 02, 2007
Staff Medical Writers

Findings by a team of Hopkins infectious disease specialists, to be published in the latest issue of The New England Journal of Medicine online June 21, showed that entecavir should not be used on its own in patients co-infected with HIV. Use of the drug led to cross-resistance to certain antiviral drugs used to treat the AIDS virus.

As a result of the study’s initial presentation in February at the 2007 Conference on Retroviruses and Opportunistic Infections (CROI), Bristol-Myers Squibb, the drug’s manufacturer, changed its product labeling to warn of the potential for HIV drug resistance, notified prescribing physicians and informed the U.S. Food and Drug Administration. The U.S. Department of Health and Human Services (HHS) also revised its treatment guidelines. HHS now recommends against using entecavir, better known by its brand name Baraclude, as the first option in treating hepatitis B in co-infected patients who are not already using drugs to suppress HIV.

“Many co-infected patients and their physicians are justifiably concerned about whether or not to use the drug,” says senior study author Chloe Thio, M.D. She notes that more than 4 million people worldwide are believed to be infected with both viruses.

“Patients contending with both diseases should consult with their physician to see if entecavir is the right drug to treat their hepatitis B in the first place, because the drug still works against the liver disease, or if they should refrain from taking it because of the potential for HIV drug resistance,” says Thio, an associate professor of medicine at The Johns Hopkins University School of Medicine.

Hepatitis B infection attacks the liver and can lead to cirrhosis, liver cancer or even death from liver failure.

“Co-infected patients already on entecavir should consult with their physician before stopping therapy and about having blood testing done to monitor for any signs of drug resistance that could potentially compromise subsequent anti-HIV therapy,” she says.

In the published study, researchers documented three cases of co-infected patients from Baltimore and San Diego who were only on entecavir therapy, yet also had decreased amounts of HIV in their blood, an indication that the drug could possibly be having some impact on their HIV disease. Detailed blood analysis of two patients showed that entecavir was interfering with HIV replication and confirmed that one patient had developed the so-called M184V mutation in HIV. This mutation is known to prevent two key drugs used to fight the immune-system disease from working. Anti-HIV drugs compromised by the mutation include lamivudine, better known as 3TC, and emtricitabine.

Since the results were presented at CROI, researchers have substantiated their findings with several more cases from across the United States, including some patients whose blood has tested positive for the presence of the M184V.

Researchers say their next step is to better understand the mechanism by which entecavir interferes with the enzyme, called reverse transcriptase, which is involved in viral replication. Their goal is to better understand how drug resistance develops, including the M184V mutation. They also plan to look for evidence of any other HIV mutations.

Keywords: HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Antiviral, Drug Development, Drug Resistance, Drugs, Entecavir, Gastroenterology, HBV, HIV, Hepatitis B Virus, Hepatology, Human Immunodeficiency Virus, Infectious Disease, Nucleoside Reverse Transcriptase Inhibitor, Pharmaceuticals, Regulatory Actions, Treatment, Viral Inhibition, Viral Therapy, Virology, Johns Hopkins University.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

McMahon MA, Jilek BL, Brennan TP, et al., The HBV drug entecavir - effects on HIV-1 replication and resistance, N Engl J Med. 2007 Jun 21;356(25):2614-21.

PubMED Related articles Search

2007-07-02
AW070701

Copyright © 2007 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.